Vivacell Bio Developed New Sepsis Treatment
The Kansas City-based firm created a therapy to reduce mortality rates from the life-threatening condition.
Updated on Oct. 2, 2026 in Biotech
Live Poll
Should medical treatments be fast-tracked to patients even if clinical trials are still limited?
Vivacell Bio Inc. has developed a new treatment, VBI-S, designed to combat sepsis by absorbing excess nitric oxide in the body. The therapy aims to address a condition that contributes to hundreds of thousands of deaths in American hospitals each year.
Why it matters
Sepsis causes a dangerous drop in blood pressure, leading to significant mortality rates among adults and children. This treatment seeks to stabilize patients by managing the body overproduction of nitric oxide during an infection.
The VBI-S treatment functions by absorbing excess nitric oxide, which is overproduced by the body during sepsis. Clinical trials demonstrated a reduction in mortality rates to 50%, a significant improvement over the 80% rate without the intervention.
The players
Vivacell Bio Inc.
This is a biotech company based in Kansas City that is working on innovative medical therapies.
Dr. Cuthbert Simpkins
He is the lead developer responsible for creating the VBI-S treatment to combat sepsis.
The details
Developed by Dr. Cuthbert Simpkins in Kansas City, the treatment focuses on mitigating the physiological collapse associated with severe sepsis. It specifically targets the excess nitric oxide that forces a critical drop in blood pressure, a primary driver of death in septic patients.
Timeline
The VBI-S treatment could be available in hospitals as soon as 2027.
The Tech Race
This development represents a major step in critical care medicine, mirroring the rigorous path of the FDA drug approval process. It positions Vivacell Bio Inc. at the forefront of a specialized niche focused on replacing older, less effective stabilization methods in emergency rooms.
The potential availability of this treatment by 2027 could drastically alter emergency medical outcomes for patients at high risk of sepsis. For families, this represents a future clinical option that may significantly lower the chances of fatality during hospital stays.
The takeaway
Sepsis remains a critical health threat claiming over 350,000 adult lives annually in the United States. Innovations like VBI-S underscore the importance of targeted therapies in stabilizing patients before the onset of life-threatening complications.
Further reading
Learn more about the latest industry breakthroughs in our Biotech section.
Source note: This article includes information reported by WENG 98.1FM, 107.5 FM & 1530 AM.
Live Poll
Should medical treatments be fast-tracked to patients even if clinical trials are still limited?
